Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
Shuji AsaiNobunori TakahashiTomonori KobayakawaAtsushi KanekoTatsuo WatanabeTakefumi KatoTsuyoshi NishiumeHisato IshikawaYutaka YoshiokaYasuhide KanayamaTsuyoshi WatanabeYuji HiranoMasahiro HanabayashiYuichiro YabeYutaka YokotaMochihito SuzukiKenya TerabeNaoki IshiguroShiro ImagamaToshihisa KojimaPublished in: Clinical rheumatology (2021)
Compared to tocilizumab, baricitinib significantly improved PGA despite similar effects on inflammation in patients with RA. Moreover, the influence of inflammation on PGA improvement differed between baricitinib and tocilizumab. Key-points • Baricitinib and tocilizumab had similar effects on inflammation in RA patients. • Baricitinib improved patient global assessment (PGA) more than tocilizumab. • Baricitinib had a higher Boolean remission rate than tocilizumab at 24 weeks. • Influence of inflammation on PGA improvement differed between the two drugs.